Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289574 · ClinicalTrials.gov registry record · Phase 2
Topical ASC-J9 Cream for Acne
A Phase 2 study, sponsored by AndroScience.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT01289574: Completed Phase 2 study, sponsored by AndroScience.
NCT01289574 is a Phase 2 study that has completed, run by AndroScience. The registered enrollment target is 181 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01289574, a Phase 2 study, has completed, sponsored by AndroScience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice daily for facial acne compared to vehicle control.
Primary Outcome
Percent change from Baseline
Interventions
- DRUG ASC-J9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01289574 record still lists
NCT01289574 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 1 intervention - of which ASC-J9 is the first listed.
NCT01289574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01289574 about?
NCT01289574 is a clinical study titled "Topical ASC-J9 Cream for Acne". To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice daily for facial acne compared to vehicle control.
What is the current status of trial NCT01289574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2011-02. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01289574?
The interventions under investigation include: ASC-J9 (DRUG).
Who is sponsoring clinical trial NCT01289574?
This trial is sponsored by AndroScience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01289574's enrollment target sits among peer trials
181 365th of 2000 higher than 1,636 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia